LEXICON PHARMACEUTICALS, INC. - COMMON STOCK (LXRX)

Historical Holders from Q2 2015 to Q3 2025

Symbol: LXRX on Nasdaq
Type / Class: Equity / COMMON STOCK
Shares outstanding: 363,214,619
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 255,139,258
Holdings value: $344,428,817
% of all portfolios: 0%
Number of holders: 121
Number of buys: 44
Number of sells: -58
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of LEXICON PHARMACEUTICALS, INC. - COMMON STOCK (LXRX)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
FMR LLC	10.5%	+9%	$26,696,274	+$2,516,037	38,137,535	+10.4%	FMR LLC	30 Jun 2025

Institutional Holders of LEXICON PHARMACEUTICALS, INC. - COMMON STOCK (LXRX)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	255,139,258	$344,428,817	-$1,111,792	$366,840	$3,378,705	$1.35	121
2025 Q2	256,310,843	$242,983,204	-$6,845,383	$130,694	$405,298	$0.9457	121
2025 Q1	265,818,368	$122,485,430	-$18,132,306	$35,608	$145,514	$0.4608	124
2024 Q4	297,662,439	$220,126,714	-$8,084,075	$131,426	$38,071	$0.7385	124
2024 Q3	288,616,985	$453,067,592	-$48,604,221	$209,424	$720,202	$1.57	134
2024 Q2	278,343,151	$467,625,172	+$175,856,984	$480,648	$1,036,728	$1.68	121
2024 Q1	171,815,966	$412,351,239	-$24,970,122	$987,840	$5,060,160	$2.4	114
2023 Q4	182,858,180	$279,771,925	-$6,759,847	$381,888	$172,890	$1.53	103
2023 Q3	188,793,708	$205,786,015	-$5,677,228	$236,530	$78,371	$1.09	109
2023 Q2	191,326,157	$438,152,499	+$104,558,326	$743,083	$74,196	$2.29	121
2023 Q1	145,600,839	$353,808,486	-$2,997,119	$229,149	$319,852	$2.43	102
2022 Q4	146,885,188	$280,547,551	-$3,977,447	$58,064	$202,922	$1.91	100
2022 Q3	148,905,062	$357,360,311	+$72,603,615	$54,000	$132,000	$2.4	98
2022 Q2	118,779,098	$220,940,693	-$2,430,736	$77,000	$163,000	$1.86	82
2022 Q1	120,193,264	$251,304,091	-$5,565,361	$58,000	$102,000	$2.09	100
2021 Q4	121,559,642	$478,894,149	-$1,466,109	$478,000	$360,000	$3.94	108
2021 Q3	121,205,281	$583,005,732	+$17,343,707	$283,000	$562,000	$4.81	96
2021 Q2	117,708,489	$540,207,653	+$2,119,118	$974,000	$1,282,000	$4.59	105
2021 Q1	121,214,904	$711,532,085	+$117,190	$1,115,000	$1,800,000	$5.87	103
2020 Q4	122,029,255	$417,334,864	+$65,690,726	$1,097,000	$1,620,000	$3.42	100
2020 Q3	104,248,250	$150,106,719	-$5,093,677	$146,000	$237,000	$1.44	83
2020 Q2	107,177,053	$213,813,923	+$4,797,305	$114,000	$175,000	$1.99	99
2020 Q1	104,815,254	$204,388,139	-$17,170,082	$133,000	$235,000	$1.95	107
2019 Q4	107,178,320	$444,778,336	+$20,431,577	$752,000	$1,246,000	$4.15	110
2019 Q3	102,423,092	$308,322,526	-$29,982,037	$1,118,000	$878,000	$3.01	95
2019 Q2	105,227,688	$661,832,362	+$7,044,227	$2,724,000	$837,000	$6.29	105
2019 Q1	104,271,703	$579,706,451	-$6,638,791	$4,902,000	$1,176,000	$5.56	112
2018 Q4	105,373,335	$699,630,313	-$17,077,199	$1,178,000	$556,000	$6.64	117
2018 Q3	107,498,975	$1,147,115,789	-$30,046,816	$2,847,000	$2,917,000	$10.67	114
2018 Q2	104,426,400	$1,253,163,056	-$371,540	$1,774,000	$4,510,000	$12	114
2018 Q1	109,754,416	$939,672,485	-$14,099,435	$1,332,000	$450,000	$8.57	118
2017 Q4	111,338,432	$1,100,040,141	-$44,224,810	$1,333,000	$1,108,000	$9.88	123
2017 Q3	110,485,325	$1,357,861,811	-$5,704,402	$12,390,000	$1,746,000	$12.29	130
2017 Q2	110,542,385	$1,818,248,643	+$18,151,870	$1,342,000	$16,089,000	$16.45	129
2017 Q1	109,854,396	$1,575,293,760	+$120,009,363	$3,820,000	$2,028,000	$14.34	130
2016 Q4	106,295,065	$1,470,204,819	-$2,532,260	$1,660,000	$5,419,000	$13.83	140
2016 Q3	106,140,794	$1,917,259,558	+$249,235	$3,744,000	$6,914,000	$18.07	138
2016 Q2	110,750,409	$1,589,249,524	+$1,094,261	$7,564,000	$5,385,000	$14.35	134
2016 Q1	110,808,225	$1,323,993,000	+$13,960,287	$3,259,000	$3,532,000	$11.95	126
2015 Q4	109,649,652	$1,459,682,001	+$54,951,710	$11,088,000	$6,907,000	$13.31	116
2015 Q3	105,860,530	$1,136,914,006	+$98,139,625	$895,000	$10,896,000	$10.74	99
2015 Q2	96,818,089	$779,385,263	+$779,385,260			$8.05	86